Comparison
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 vs 17q11 2 Microduplication Syndrome C3495679
Clinical comparison between 3 Beta Hydroxysteroid Dehydrogenase Deficiency and 17q11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
A rare genetic disorder affecting adrenal hormone production. It can cause ambiguous genitalia, salt-wasting crises, and hormonal imbalances. Treatment requires hormone replacement therapy and careful monitoring.
17q11 2 Microduplication Syndrome C3495679
A genetic disorder caused by duplication of a segment on chromosome 17. Individuals may have developmental delays, behavioral concerns, and physical features. Treatment focuses on early intervention.
6 comparison axes
Onset
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
0-null
17q11 2 Microduplication Syndrome C3495679
0-null
Onset patterns differ
Severity
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
severe
17q11 2 Microduplication Syndrome C3495679
moderate
Different severity levels
Chronic
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
Chronic
17q11 2 Microduplication Syndrome C3495679
Chronic
Differing course
Communicable
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
No
17q11 2 Microduplication Syndrome C3495679
No
Different transmission
Body System
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
endocrine
17q11 2 Microduplication Syndrome C3495679
congenital
Same/different system
Category
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
endocrine
17q11 2 Microduplication Syndrome C3495679
genetic
Different category
Bottom line
3-beta-hydroxysteroid-dehydrogenase-deficiency-C0342471 and 17q11-2-microduplication-syndrome-C3495679 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 | 17q11 2 Microduplication Syndrome C3495679 | Discriminating power |
|---|---|---|---|
| Salt-wasting crisis | May occur with adrenal insufficiency; urgent evaluation is needed. | Not a described core feature of the microduplication. | High |
| Genital development | Ambiguous genitalia may occur from disordered steroid production. | Genital ambiguity is not established as characteristic. | Moderate |
| Development and behavior | Not the primary described presentation, though illness may affect development. | Developmental delay and behavioral concerns may be present. | Moderate |
When to favor each condition
Choose 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 when
Infant with suspected adrenal crisis
Salt wasting and hormonal imbalance fit the endocrine disorder better.
High
Abnormal steroid profile
A pattern suggesting impaired steroidogenesis warrants specialist interpretation.
Moderate
Ambiguous genitalia with endocrine clues
This combination supports evaluating adrenal steroid disorders.
Moderate
Choose 17q11 2 Microduplication Syndrome C3495679 when
Developmental delay with dysmorphic features
Chromosomal microarray is more relevant than adrenal testing alone.
Moderate
Known 17q11.2 duplication
A confirmed genomic finding supports this diagnosis.
High
Behavioral concerns without adrenal crisis
This pattern aligns more with the microduplication description.
Low
How key tests differ
| Test | 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 | 17q11 2 Microduplication Syndrome C3495679 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | May show disordered adrenal steroid production; cutoffs are not specified here. | No characteristic steroid abnormality is established. | Abnormal results require clinician and laboratory interpretation. |
| Chromosomal microarray | Not expected to identify the enzyme deficiency. | May detect a 17q11.2 duplication when present. | A genomic result needs correlation with phenotype. |
| Electrolytes during illness | Salt wasting may cause clinically important electrolyte disturbance. | No specific electrolyte pattern is established. | Results indicate physiology, not a diagnosis by themselves. |
Prognosis comparison
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
- Outcome
- Chronic and potentially severe; outcomes depend on recognition and endocrine care.
- Factors
- Salt-wasting episodes, hormone imbalance, and monitoring adherence.
17q11 2 Microduplication Syndrome C3495679
- Outcome
- Usually described as moderate and chronic, with variable developmental impact.
- Factors
- Developmental profile, behavioral needs, and access to early intervention.
Time frame: Lifelong follow-up is generally expected; precise outcomes are not established here.
Confirmed diagnosis, complications, and individualized support influence course.
Complications comparison
| Complication | Presentation |
|---|---|
| Adrenal crisis | A potentially severe complication requiring urgent care. Not described as typical. Exact risk cannot be quantified from the supplied data. |
| Developmental impairment | Possible secondary impact is not well defined here. Developmental delay may be a primary concern. Severity varies and should be assessed individually. |
| Behavioral difficulties | Not established as a core complication. Behavioral concerns may occur. Support needs depend on evaluation. |
Patient education highlights
- HighUrgent symptoms
Seek emergency care for vomiting, lethargy, dehydration, or suspected salt-wasting illness.
- MediumDiagnosis confirmation
Hormone abnormalities and genomic findings require specialist confirmation.
- LowLong-term support
Monitoring, hormone care, or developmental intervention depends on the confirmed condition.